» Articles » PMID: 36257549

Serum Neutralization of SARS Coronavirus 2 Omicron Sublineages BA.1 and BA.2 and Cellular Immune Responses 3 months After Booster Vaccination

Abstract

Objectives: We investigated serum neutralizing activity against BA.1 and BA.2 Omicron sublineages and T cell response before and 3 months after administration of the booster vaccine in healthcare workers (HCWs).

Methods: HCWs aged 18-65 years who were vaccinated and received booster doses of the BNT162b2 vaccine were included. Anti-SARS coronavirus 2 IgG levels and cellular response (through interferon γ ELISpot assay) were evaluated in all participants, and neutralizing antibodies against Delta, BA.1, and BA.2 were evaluated in participants with at least one follow-up visit 1 or 3 months after the administration of the booster dose.

Results: Among 118 HCWs who received the booster dose, 102 and 84 participants attended the 1-month and 3-month visits, respectively. Before the booster vaccine dose, a low serum neutralizing activity against Delta, BA.1, and BA.2 was detectable in only 39/102 (38.2%), 8/102 (7.8%), and 12/102 (11.8%) participants, respectively. At 3 months, neutralizing antibodies against Delta, BA.1, and BA.2 were detected in 84/84 (100%), 79/84 (94%), and 77/84 (92%) participants, respectively. Geometric mean titres of neutralizing antibodies against BA.1 and BA.2 were 2.2-fold and 2.8-fold reduced compared with those for Delta. From 1 to 3 months after the administration of the booster dose, participants with a recent history of SARS coronavirus 2 infection (n = 21/84) had persistent levels of S1 reactive specific T cells and neutralizing antibodies against Delta and BA.2 and 2.2-fold increase in neutralizing antibodies against BA.1 (p 0.014). Conversely, neutralizing antibody titres against Delta (2.5-fold decrease, p < 0.0001), BA.1 (1.5-fold, p 0.02), and BA.2 (2-fold, p < 0.0001) declined from 1 to 3 months after the administration of the booster dose in individuals without any recent infection.

Discussion: The booster vaccine dose provided significant and similar response against BA.1 and BA.2 Omicron sublineages; however, the immune response declined in the absence of recent infection.

Citing Articles

An Analysis of the Neutralizing Antibodies against the Main SARS-CoV-2 Variants in Healthcare Workers (HCWs) Vaccinated against or Infected by SARS-CoV-2.

Immordino P, Pisciotta V, Amodio E, Bonura C, Bonura F, Cacioppo F Vaccines (Basel). 2023; 11(11).

PMID: 38006034 PMC: 10674949. DOI: 10.3390/vaccines11111702.

References
1.
Evans J, Zeng C, Qu P, Faraone J, Zheng Y, Carlin C . Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host Microbe. 2022; 30(8):1093-1102.e3. PMC: 9035359. DOI: 10.1016/j.chom.2022.04.014. View

2.
Muecksch F, Weisblum Y, Barnes C, Schmidt F, Schaefer-Babajew D, Wang Z . Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021; 54(8):1853-1868.e7. PMC: 8323339. DOI: 10.1016/j.immuni.2021.07.008. View

3.
Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M . Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg Microbes Infect. 2022; 11(1):477-481. PMC: 8820826. DOI: 10.1080/22221751.2022.2030200. View

4.
Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View

5.
Perez-Then E, Lucas C, Silva Monteiro V, Miric M, Brache V, Cochon L . Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022; 28(3):481-485. PMC: 8938264. DOI: 10.1038/s41591-022-01705-6. View